Earth Science Tech, Inc. (ETST) Orders First Commercial Production Run of Hygee™ Kits

Launch of new medical device to fight STIs slated for early 2019

DORAL, Florida, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces the production of the first commercial production run of Hygee™, its new, original medical device to fight sexually transmitted infections (STIs). The official launch is scheduled for early 2019.

After numerous partnerships, tests, distribution agreements and prepping, ETST has officially ordered a first production run of Hygeeâ„¢. Initial marketing will target North America, South America, Asia and Africa, and the Company will package Hygeeâ„¢ in English, French, Portuguese, Spanish, Vietnamese and Arabic to reach an wide audience of consumers.  These languages are mother tongues for 1.5 billion people, with many other ethnic groups using English as a second language. By offering Hygeeâ„¢ in different languages, ETST can reach the majority of individuals globally, as well as those in the Company’s current agreed distribution network, shared in November.

The Hygeeâ„¢ self-sampling kit includes a discreet, wearable medical device that enables a woman to anonymously test for STIs such as chlamydia. Testing for this disease is particularly important for pregnant women, who must be screened for chlamydia infections to minimize the risk of transmission of the infection to their babies during childbirth. In any given year, approximately 8 million women give birth in the United States, Canada, Brazil, Mexico, Morocco, Djibouti, and Vietnam where Hygeeâ„¢ will first be offered.

While this niche represents a considerable market for the Hygeeâ„¢ medical device, opportunity exists well beyond pregnant women. The World Health Organization recommends that all sexually active women aged 15 to 25 get tested yearly for chlamydia, representing a market of about 500 million women worldwide.

Dr. Michel Aube, ETST’s CEO and chief science officer, states, “No other existing method of collecting genital specimens from women is more convenient or more efficient than Hygeeâ„¢. Through intentional design, Hygeeâ„¢ is a ‘mistake proof’ medical device with extremely simple instructions that allow any woman, regardless of age or education the assurance of correctly using the kit on the first try.  With roughly 130 million new chlamydia cases diagnosed yearly, according to the WHO, Hygeeâ„¢ is dedicated to this area of women’s health.”

ETST’s projections for Hygeeâ„¢ anticipate strong sales growth in years two and three after product launch. As soon as year one, sales of Hygeeâ„¢ and the associated in vitro molecular diagnoses should reach between $1.5 million and $2.5 million USD. Second year sales should reach $1 million monthly and up to $20 million yearly as early as the third year. These numbers are supported by the fact that chlamydia is a global issue; that the company’s network of distributors is worldwide; and that the thin structure of the device and the stability of the specimen collected with Hygeeâ„¢ ensures that it can be easily dispersed on all continents.   

“We believe that ETST has developed the best tool on the market to fight STIs, which will provide an exceptional service to women who use Hygeeâ„¢,”  states Nickolas S. Tabraue, the company’s president, director, and chairman. “The production of the first batch of Hygeeâ„¢ is very exciting. Our team believed in the success of Hygeeâ„¢ from the first day we acquired it. Now, we will do everything possible to spread this fabulous medical device everywhere on the planet to protect women and their future babies from the terrible, adverse effects of chlamydia and other STIs.”

About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.

• 1